# A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors

> **NCT06001580** · PHASE1 · COMPLETED · sponsor: **BioRay Pharmaceutical Co., Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** BR101

## Key facts

- **NCT ID:** NCT06001580
- **Lead sponsor:** BioRay Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-11
- **Primary completion:** 2023-10-27
- **Final completion:** 2024-02-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001580, "A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06001580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*